Greg Harrison
Stock Analyst at Scotiabank
(3.39)
# 964
Out of 4,915 analysts
94
Total ratings
54.17%
Success rate
2.46%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $71 → $65 | $37.22 | +74.64% | 7 | Jul 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $9 → $4 | $3.05 | +31.15% | 8 | Jul 25, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $2.04 | +439.22% | 1 | Jul 14, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Sector Outperform | $32 → $35 | $12.21 | +186.65% | 2 | Jul 2, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $321 → $315 | $274.70 | +14.67% | 4 | Jun 11, 2025 | |
| VERA Vera Therapeutics | Maintains: Sector Outperform | $65 → $55 | $20.79 | +164.55% | 3 | Jun 2, 2025 | |
| LQDA Liquidia | Maintains: Sector Outperform | $36 → $37 | $18.69 | +97.97% | 6 | May 28, 2025 | |
| KROS Keros Therapeutics | Maintains: Sector Outperform | $41 → $26 | $14.33 | +81.50% | 6 | May 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $28 → $20 | $22.34 | -10.47% | 4 | May 8, 2025 | |
| GERN Geron | Downgrades: Sector Perform | $4 → $1.5 | $1.15 | +30.43% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $450 → $442 | $456.87 | -3.25% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $52 → $55 | $47.27 | +16.35% | 6 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $338 → $342 | $392.24 | -12.81% | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $19.71 | +102.94% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $59.76 | +25.50% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $27 → $32 | $15.45 | +107.12% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $9.83 | +83.21% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $11.58 | +89.98% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $11.64 | +681.79% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $12.85 | -6.61% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.54 | +179.28% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $14.15 | +175.62% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.51 | +497.61% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $3.87 | -22.48% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.70 | +4,017.65% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $18.34 | +194.44% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $21.68 | +315.13% | 5 | Mar 14, 2022 |
Agios Pharmaceuticals
Jul 28, 2025
Maintains: Sector Outperform
Price Target: $71 → $65
Current: $37.22
Upside: +74.64%
Rocket Pharmaceuticals
Jul 25, 2025
Downgrades: Neutral
Price Target: $9 → $4
Current: $3.05
Upside: +31.15%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $2.04
Upside: +439.22%
Arcturus Therapeutics Holdings
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $12.21
Upside: +186.65%
United Therapeutics
Jun 11, 2025
Maintains: Neutral
Price Target: $321 → $315
Current: $274.70
Upside: +14.67%
Vera Therapeutics
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $20.79
Upside: +164.55%
Liquidia
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $18.69
Upside: +97.97%
Keros Therapeutics
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $14.33
Upside: +81.50%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $22.34
Upside: -10.47%
Geron
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.15
Upside: +30.43%
May 6, 2025
Maintains: Sector Perform
Price Target: $450 → $442
Current: $456.87
Upside: -3.25%
Apr 30, 2025
Maintains: Sector Outperform
Price Target: $52 → $55
Current: $47.27
Upside: +16.35%
Mar 31, 2025
Maintains: Sector Outperform
Price Target: $338 → $342
Current: $392.24
Upside: -12.81%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $19.71
Upside: +102.94%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $59.76
Upside: +25.50%
Feb 12, 2025
Maintains: Sector Outperform
Price Target: $27 → $32
Current: $15.45
Upside: +107.12%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $9.83
Upside: +83.21%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $11.58
Upside: +89.98%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $11.64
Upside: +681.79%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $12.85
Upside: -6.61%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.54
Upside: +179.28%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $14.15
Upside: +175.62%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.51
Upside: +497.61%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $3.87
Upside: -22.48%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $1.70
Upside: +4,017.65%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $18.34
Upside: +194.44%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $21.68
Upside: +315.13%